# Correlation between plasmacytoid dendritic cell activation and suppression of subjective physical symptoms following Lactobacillus paragasseri SBT2055 ingestion: a randomized, double-blind, placebo-controlled, parallel-group comparative study

**Authors:** Eiji Kobatake, Shukuko Ebihara, Masaya Miyoshi, Toshiharu Namba, Toshinobu Arai

PMC · DOI: 10.3389/fnut.2025.1722081 · Frontiers in Nutrition · 2026-01-12

## TL;DR

A study found that ingesting a specific probiotic reduced common cold symptoms in healthy adults, possibly by activating certain immune cells.

## Contribution

This study demonstrates a novel link between probiotic intake, immune cell activation, and reduced subjective physical symptoms.

## Key findings

- LG2055 ingestion significantly reduced nine physical symptoms in participants.
- LG2055 increased pDC activation markers in younger participants but not in middle-aged individuals.
- The probiotic improved physical condition by activating plasmacytoid dendritic cells.

## Abstract

This study examined the relationship between physical condition and plasmacytoid dendritic cell (pDC) activation in healthy adults who ingested Lactobacillus paragasseri SBT2055 (LG2055).

This randomized, double-blind, placebo-controlled, parallel-group comparative study involved 200 participants who were randomly divided into the LG2055 and placebo groups. The participants ingested one bottle of drinkable yogurt with or without LG2055 daily for 12 weeks. A daily physical health questionnaire on local and systemic symptoms of the common cold was used as the primary outcome. The secondary outcomes were pDC activity, pDC frequency, and IFN-α production by peripheral blood mononuclear cells.

Of the 200 participants, 196 completed the intake, and after excluding 8 participants, 188 (95 in the LG2055 group and 93 in the placebo group) were analyzed. The LG2055 group showed a significantly lower ratio of “with symptoms” during the intake period for nine symptoms (nasal congestion, sneezing, hoarseness, cough, headache, general malaise, chills, feverishness, and feeling unwell) (Chi-squared test, p < 0.05). Based on reports that aging correlates with numerical and functional decline in pDCs, stratified analysis was conducted and revealed that changes in the expression levels of cell surface markers (CD86, HLA-DR, and CD40) in pDCs were significantly higher in the LG2055 group among young participants (<40 years), whereas LG2055 intake suppressed changes in physical condition. In middle-aged participants (≥40 years), LG2055 neither activated pDCs nor strongly influenced their physical condition.

The study results indicate that pDC activation by LG2055 contributes to the maintenance of physical condition and suggests that LG2055 improves subjective symptoms by activating pDCs.

https://www.umin.ac.jp/ctr/index.htm, identifier UMIN000055950.

## Linked entities

- **Proteins:** CD86 (CD86 molecule), CD40 (CD40 molecule), IFN1@ (interferon, type 1, cluster)

## Full-text entities

- **Genes:** CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}
- **Diseases:** cough (MESH:D003371), headache (MESH:D006261), nasal congestion (MESH:D009668), common cold (MESH:D003139), hoarseness (MESH:D006685)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12832821/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12832821/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12832821/full.md

---
Source: https://tomesphere.com/paper/PMC12832821